Anlon Healthcare Ltd

Anlon Healthcare Ltd share price inched up 3.11% to Rs 25.2 after the company's net profit jumped 107.49% to Rs 17.18 crore, while revenue from operations gained significantly 20.61% to Rs 105.61 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.44%. It has improved by 5.74% over last one week and ticked higher by 0.60% in last one month while the market capitalization of Anlon Healthcare Ltd has slipped by 1.37% and 72.37% in the same period respectively. Profit before tax (PBT) of Anlon Healthcare Ltd stood at Rs 23.47 crore in Q3 FY26, jumping 88.51% year-on-year, and expanding by 71.82% quarter-on-quarter. EBITDA came in at Rs 25 crore, surging by 84.14% YoY and rallying 62.20% sequentially. Total expenses advancing by 11.34% to Rs 81.32 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 48.69 crore, tumbling by 33.34% YoY, while employee benefits expense was at Rs 2.59 crore, surging 32.82% YoY. For the TTM ended FY26, revenue from operations soared by 59.54% to Rs 191.91 crore, while net profit surged by 41.76% to Rs 29.09 crore, compared to previous TTM. EBITDA jumped by 3078% to Rs 47.25 crore, and PBT witnessed a strong rise of 58.09% to Rs 42.51 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 79.44 crore in FY26, as against Rs 22.55 crore in FY25. Anlon Healthcare Ltd rallied 100.80% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 12.76% during the same period.

Anlon Healthcare Ltd share price gained 3.11% to Rs 25.2 after the company's net profit jumped 107.49% to Rs 17.18 crore, while revenue from operations gained significantly 20.61% to Rs 105.61 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.26%. It has improved by 4.43% over last one week and ticked higher by 0.60% in last one month while the market capitalization of Anlon Healthcare Ltd has marginally improved by 3.49% and 72.37% in the same period respectively. Profit before tax (PBT) of Anlon Healthcare Ltd stood at Rs 23.47 crore in Q3 FY26, surging by 88.51% year-on-year, and jumping 71.82% quarter-on-quarter. EBITDA came in at Rs 25 crore, rallying 84.14% YoY and expanding by 62.20% sequentially. Total expenses went up by 11.34% to Rs 81.32 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 48.69 crore, slumping by 33.34% YoY, while employee benefits expense was at Rs 2.59 crore, soaring 32.82% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 59.54% to Rs 191.91 crore, while net profit surged by 41.76% to Rs 29.09 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 3078% to Rs 47.25 crore, and PBT surged 58.09% to Rs 42.51 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 79.44 crore in FY26, as against Rs 22.55 crore in FY25. Anlon Healthcare Ltd rallied 93.66% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.45% during the same period.

Anlon Healthcare Limited submitted a certificate to the BSE Limited and the National Stock Exchange of India Ltd. under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, with Kfin Technologies Limited acting as the Registrar and Share Transfer Agent.

Anlon Healthcare Limited will hold a board meeting on Tuesday, October 13, 2026, to discuss business expansion plans in India and/or overseas, and the potential raising of funds through equity, debt, hybrid instruments, borrowings, or a combination thereof, subject to applicable regulatory approvals.

Anlon Healthcare Limited informed the BSE Limited and the National Stock Exchange of India Ltd. that the trading window for dealing in the company's securities will be closed from Thursday, October 01, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, for promoters, promoter group, directors, key managerial personnel, designated employees, connected/designated persons, and their immediate relatives.

Anlon Healthcare Ltd. announced that Brickwork Ratings (BWR) has assigned a rating of BWR BBB / Stable to its Fund Based Long Term facilities amounting to Rs. 23.60 crore, alongside an assignment for Bank Loan facilities also rated BBB / Stable, while simultaneously removing a previous rating of BB+ Stable and withdrawing a rating of C from the ISSUER NOT COOPERATING* category; the rating agency also continues a rating of B- Stable under the ISSUER NOT COOPERATING* / Downgrade designation. The rating actions reflect Anlon Healthcare’s operating income of Rs. 176.54 crore for FY26, a net worth of Rs. 209.77 crore, and projected revenues of Rs. 270 crore for FY2027, alongside a moderate cash and bank balance of Rs. 3.41 crore, and net cash accruals of Rs. 30.92 crore, with no ratings assigned by RBI, SEBI, or MCA beyond those related to instruments originated or raised by other entities.

Anlon Healthcare Limited plans to acquire shares in Anlon Medicos Private Limited, a subsidiary, for Rs 500 Crore, alongside sales and purchases of goods and services also valued at Rs 500 Crore, representing 28.33% of the company’s turnover. The transactions, expected to strengthen manufacturing capacity and support long-term growth, are considered material and will be conducted at arm’s length pricing. Notably, Anlon Medicos currently holds a negative net worth of Rs 433.61 Lakhs as of March 31, 2026, and has reported a loss after tax of Rs 489.60 Lakhs for the same period, raising concerns about its financial viability. Directors Punitkumar Rasadia and Meet Atulkumar Vachhani, who hold positions in both companies, are considered interested parties in the proposed transactions, which are slated to continue until the next annual general meeting.

Anlon Healthcare Limited disclosed two related party transactions totaling Rs 5000 Lakhs (approximately $60 million USD) with Anlon Medicos Private Limited, fulfilling requirements outlined in SEBI regulations and circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026. The transactions, described as sales and purchases, represent 28.33% of Anlon Healthcare’s turnover and are considered commercially beneficial, supporting long-term growth plans. Directors Punitkumar Rasadia and Meet Atulkumar Vachhani have interests in the transactions, which are stated to be at arm’s length. Notably, Anlon Medicos Private Limited is a subsidiary of Anlon Healthcare, with AHL holding a 56.83% shareholding, and the related party reported a loss of Rs 489.60 Lakhs and a negative net worth of Rs 433.61 Lakhs, prompting scrutiny regarding the viability of the transactions. The second related party transaction appears to be a duplicate entry, and requires clarification.

Anlon Healthcare is undertaking a share swap with Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL) through a preferential allotment of equity shares, potentially issuing up to 8,58,83,617 shares at a price of Rs 17.85 per share. The swap ratio is 1 share of Anlon for 14.45 shares of AOPL, involving up to 160 shareholders and approximately 20,34,43,043 shares, while the ratio for BLPL is 1 share of Anlon for 8.96 shares, impacting up to 173 shareholders and roughly 22,99,000 shares. AOPL and BLPL operate within the pharmaceutical/organic and pharmaceutical/lifescience sectors, respectively, and both companies reported a turnover of Rs 380.39 crore in 2023-24, Rs 3,038.20 crore in 2024-25, and Rs 3,126.64 crore in 2025-26. The share swap will significantly increase the number of outstanding Anlon Healthcare shares, diluting existing shareholder ownership, and the final number of shares issued will depend on acceptance rates from shareholders of AOPL and BLPL.

Anlon Healthcare Limited has postponed its Board of Directors meeting, initially scheduled for Tuesday, August 11, 2026, to Thursday, August 13, 2026, due to administrative reasons, according to a regulatory filing with the BSE Limited and the National Stock Exchange of India Ltd.